Page 228 - 2021_02-Haematologica-web

S. Nakahata et al.
24.Paulsson K, An Q, Moorman AV, et al.
Methylation of tumour suppressor gene pro- moters in the presence and absence of tran- scriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. Br JHaematol. 2009;144(6):838-847.
25. Murray PG, Fan Y, Davies G, et al. Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lym- phoma cells from apoptosis. Am J Pathol. 2010;177(3):1480-1490.
26. Fu L, Gao Z, Zhang X, et al. Frequent con- comitant epigenetic silencing of the stress- responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma. Int J Cancer. 2009; 124(7):1572-1578.
27. Koma Y, Ito A, Wakayama T, et al. Cloning of a soluble isoform of the SgIGSF adhesion molecule that binds the extracellular domain of the membrane-bound isoform. Oncogene. 2004;23(33):5687-5692.
28. Hagiyama M, Ichiyanagi N, Kimura KB, Murakami Y, Ito A. Expression of a soluble isoform of cell adhesion molecule 1 in the brain and its involvement in directional neu- rite outgrowth. Am J Pathol. 2009; 174(6):2278-2289.
29.Nagara Y, Hagiyama M, Hatano N, et al. Tumor suppressor cell adhesion molecule 1 (CADM1) is cleaved by adisintegrin and metalloprotease 10 (ADAM10) and subse- quently cleaved by γ-secretase complex. Biochem Biophys Res Commun. 2012; 417(1):462-467.
30. Moiseeva EP, Leyland ML, Bradding P. CADM1 is expressed as multiple alterna- tively spliced functional and dysfunctional isoforms in human mast cells. Mol Immunol. 2013;53(4):345-354.
31. Shirakabe K, Omura T, Shibagaki Y, et al. Mechanistic insights into ectodomain shed-
ding: susceptibility of CADM1 adhesion molecule is determined by alternative splic- ing and O-glycosylation. Sci Rep. 2017; 7:46174.
32. Eglen RM, Reisine T, Roby P, et al. The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics. 2008;1:2-10.
33. McGiven JA, Sawyer J, Perrett LL, et al. A new homogeneous assay for high through- put serological diagnosis of brucellosis in ruminants. J Immunol Methods. 2008; 337(1):7-15.
34. Kurosawa G, Akahori Y, Morita M, et al. Comprehensive screening for antigens over- expressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci U S A. 2008;105(20):7287- 7292.
35. Tsukasaki K, Tobinai K. HTLV-1-associated T-cell diseases. In: Francine F, editor. T-cell lymphomas. New York: Humana; 2013. pp. 113-135.
36. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progres- sion in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211-1219.
37. Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015; 47(11):1304-1315.
38. Shah UA, Chung EY, Giricz O, et al. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018; 132(14):1507-1518.
39.Sarkar B, Nishikata I, Nakahata S, et al. Degradation of p47 by autophagy con- tributes to CADM1 overexpression in ATLL cells through the activation of NF-κB. Sci Rep. 2019;9(1):3491.
40. Manivannan K, Rowan AG, Tanaka Y, Taylor GP, Bangham CR. CADM1/TSLC1
identifies HTLV-1-infected cells and deter- mines their susceptibility to CTL-mediated lysis. PLoS Pathog. 2016;12(4):e1005560.
41. Seidler S, Zimmermann HW, Weiskirchen R, Trautwein C, Tacke F. Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes. BMC Gastroenterol. 2012;12:38.
42.Masuda M, Maruyama T, Ohta T, et al. CADM1 interacts with Tiam1 and pro- motes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J Biol Chem. 2010;285(20):15511-15522.
143. Boles KS, Barchet W, Diacovo T, Cella M, Colonna M. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood. 2005;106(3):779- 786.
44s. Kannagi M, Hasegawa A, Nagano Y, Kimpara S, Suehiro Y. Impact of host immu- nity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. Retrovirology. 2019;16(1):23.
45. Yoneshige A, Hagiyama M, Inoue T, et al. Increased ectodomain shedding of cell adhe- sion molecule 1 as a cause of type II alveolar epithelial cell apoptosis in patients with idiopathic interstitial pneumonia. Respir Res. 2015;16:90.
46. Mimae T, Hagiyama M, Inoue T, et al. Increased ectodomain shedding of lung epithelial cell adhesion molecule 1 as a cause of increased alveolar cell apoptosis in emphysema. Thorax. 2014;69(3):223- 231.
47. Inoue T, Hagiyama M, Yoneshige A, et al. Increased ectodomain shedding of cell adhe- sion molecule 1 from pancreatic islets in type 2 diabetic pancreata: correlation with hemoglobin A1c levels. PLoS One. 2014; 9(6):e100988.
542
haematologica | 2021; 106(2)